Skip to search formSkip to main contentSkip to account menu

0.5 ML Leuprolide Acetate 60 MG/ML Prefilled Syringe [Eligard]

Known as: ELIGARD KIT, 0.5 ML Eligard 60 MG/ML Prefilled Syringe, LEUPROLIDE ACETATE (ELIGARD) 30MG (4 MONTH) INJ,SUSP,LA 
National Institutes of Health

Related topics

Related topics

15 relations
Drug AllergyEligardEndometrial NeoplasmsEndometriosis

Broader (1)

Leuprolide Acetate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
In Situ Forming Depot as Sustained-Release Drug Delivery Systems.
In situ forming systems can serve as promising alternative to existing long acting injectables like disperse systems and… 
2014
2014
Eligard® (leuprorelina): falta de eficacia clínica debida a errores durante el proceso de reconstitución y administración del medicamento
Se han notificado al Sistema Español de Farmacovigilancia varios casos de falta de eficacia clínica asociada a errores durante el… 
2014
2014
Efficacy and tolerability of 1- and 3-month leuprorelin acetate depot formulations (Eligard®/Depo-Eligard®) for advanced prostate cancer in daily practice: a Belgian prospective non-interventional…
Introduction The 1-, 3- and 6- month biodegradable polymer matrix depot formulations of leuprorelin acetate (Eligard®/Depo… 
Review
2013
Review
2013
Leuprolide acetate 1-, 3- and 6-monthly depot formulations in androgen deprivation therapy for prostate cancer in nine European countries: evidence review and economic evaluation
Objective Leuprolide is an established luteinizing hormone–releasing hormone (LHRH) agonist used as first-line treatment in… 
2011
2011
A 6-month depot formulation of leuprolide acetate is safe and effective in daily clinical practice: a non-interventional prospective study in 1273 patients
BackgroundTestosterone stimulates growth in many prostate tumours. The established GnRH analogue leuprolide acetate is… 
Review
2009
Review
2009
Improving Flexibility and Quality of Life for Your Patients: A Must?
Review
2008
Review
2008
Optimal Control of Testosterone: A Clinical Case-Based Approach of Modern Androgen-Deprivation Therapy
Review
2006
Review
2006
Eligard®: Advantages for Optimal Testosterone Control
2005
2005
How Good do Current LHRH Agonists Control Testosterone? Can this be Improved with Eligard®?
2005
2005
Eligard®: Pharmacokinetics, Effect on Testosterone and PSA Levels and Tolerability
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)